Financial PerformanceRevenue for the dispensing segment increased by an impressive 57% year over year, surpassing prior estimates.
Growth PotentialThere is a demand seeding a durable 20%+ topline growth pipeline for The Oncology Institute.
Guidance And OutlookOncology Institute, Inc. raised full-year 2025 guidance for revenue and narrowed the expected range for adjusted EBITDA, with a slight increase in the midpoint.